Skip to main content
main-content

Rheumatoid arthritis

Comorbidities

The importance of early diagnosis and treatment of inflammatory arthritis

In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.

19-12-2018 | Diagnosis and screening | Podcast | Audio

The importance of early diagnosis and treatment of inflammatory arthritis

In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.

04-12-2018 | Comorbidities | Article

Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study

Panopoulos S et al. Arthritis Res Ther 2018. doi: 10.1186/s13075-018-1771-0

26-11-2018 | Rheumatoid arthritis | Article

Chronic opioid use in rheumatoid arthritis: Prevalence and predictors

Lee YC. Arthritis Rheumatol 2018. doi: 10.1002/art.40789

21-11-2018 | Rheumatoid arthritis | News

ALC measurement sufficient to monitor infection risk in tofacitinib-treated RA

An evaluation of the temporal effects of tofacitinib on lymphocyte counts suggests that monitoring of absolute lymphocyte count alone is sufficient to minimize the risk for serious infection in patients with rheumatoid arthritis.

Source:

Arthritis Rheum 2018; doi:10.1002/art.40780

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

Author:
Eoin Feeney

05-11-2018 | Rheumatoid arthritis | News

Elevated autoimmune thyroid disease risk in RA patients declines over time

Study findings suggest that patients with rheumatoid arthritis have an increased risk for autoimmune thyroid disease relative to the general population in the period leading up to arthritis diagnosis, but the risk reduces after this time.

Source:

JAMA Netw Open 2018; 1: e183567

25-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

Improving immune response against influenza in patients with RA

Inés Colmegna talks to us about her study showing the impact of a high-dose influenza vaccine on the immune response of patients with rheumatoid arthritis (11:17).

24-10-2018 | Cardiovascular disease | ACR/ARHP 2018 | Video

Looking to collaborative models of care to improve primary prevention of CVD in patients with inflammatory arthritis

Lihi Eder describes a new model of care based on collaboration between cardiologists and rheumatologists to better manage cardiovascular risk factors in patients with inflammatory arthritis (5:56).

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

Interstitial lung disease risk linked to rheumatoid arthritis disease severity

Moderate-to-high rheumatoid arthritis disease activity is associated with a twofold increased risk for associated interstitial lung disease, compared with remission or low disease activity, study findings show.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

Expert commentary: Influzena vaccination in RA patients

Infectious disease specialist Kevin Winthrop comments on the study by Inés Colmegna and colleagues looking at the effects of a high-dose influenza vaccine on immune response in patients with rheumatoid arthritis (6:27).

MUC5B promoter variant identified as a risk factor for RA-ILD

Philippe Dieudé discusses the results of a study demonstrating that the MUC5B promoter variant rs35705950 is linked to rheumatoid arthritis-associated interstitial disease susceptibility (3:01).

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

MUC5B promoter variant identified as a risk factor for RA-ILD

Philippe Dieudé discusses the results of a study demonstrating that the MUC5B promoter variant rs35705950 is linked to rheumatoid arthritis-associated interstitial disease susceptibility (3:01).

High-dose influenza vaccine enhances immune response in RA patients

Administration of a high-dose influenza vaccine results in an improved humoral immune response when given to patients with rheumatoid arthritis, suggest findings from a randomized controlled trial.

22-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

Glucocorticoids add to increased herpes zoster risk in patients taking tofacitinib for RA

The increased risk for herpes zoster in rheumatoid arthritis patients taking tofacitinib is further doubled with the concomitant use of glucocorticoids, show real-world data for more than 8000 patients.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018
Arthritis Care Res 2018; doi:0.1002/acr.23769

21-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

High-dose influenza vaccine enhances immune response in RA patients

Administration of a high-dose influenza vaccine results in an improved humoral immune response when given to patients with rheumatoid arthritis, suggest findings from a randomized controlled trial.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018 

10-10-2018 | Mental health | Editorial | Article

Why depression and anxiety matter in patients with inflammatory arthritis

Advisory Board member Susan Bartlett discusses the prevalence of mental health comorbidities in patients with inflammatory arthritis, and their impact on disease symptoms and quality of life.

Author:
Susan Bartlett

Why depression and anxiety matter in patients with inflammatory arthritis

Advisory Board member Susan Bartlett discusses the prevalence of mental health comorbidities in patients with inflammatory arthritis, and their impact on disease symptoms and quality of life.

image credits